
Opinion|Videos|May 14, 2024
Persistence and Discontinuation Rates for Non-Statin Therapies in ASCVD
Clinical insights on how real-world treatment persistence and discontinuation rates compare between the various non-statin therapies and the factors that contribute to these differences.
Advertisement
Episodes in this series

Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
ADCs in Breast Cancer: Shaping the Future of HER2– and TROP2-Targeted Therapy
2
FDA Approves Gepotidacin for Urogenital Gonorrhea in Adult and Pediatric Patients
3
Emerging Data from the DESTINY-Breast Trials Signal Shift in Standards of Care for HER2-Positive Breast Cancer
4
Study: Many Patients Switching Biologics Because of Perceived Lack of Efficacy Treating Asthma
5






















































































































































































































